ASH
MRD Negativity After Lymphoma Therapy Predicted Outcomes Better Than Single PET-CT Scan in Study
Premium
Researchers concluded based on data shared at ASH that ctDNA testing can accurately predict who can forgo salvage therapy and may limit the number of tests.
Variant Screening Tool Flags Possible Pathogenic Germline Variants in Multiple Myeloma Patients
Premium
The tool developed by Mount Sinai researchers is designed to identify variants associated with heritable cancer risk within somatic genetic sequencing results.
Circulating Tumor DNA Helps ID First-Line Lymphoma Patients for Roche's Columvi, R-CHOP
Patients whose lymphomas were considered high-risk according to ctDNA analyses were less likely to benefit from the widely used chemotherapy regimen.
Researchers Showcase New Scores, Biomarkers, Signatures for Predicting CAR T-Cell Outcomes at ASH
Premium
Across three studies, researchers demonstrated how various biomarkers can inform trial design and predict lymphoma patients' outcomes on CAR T-cell therapy.
Polygenic Score May Help Personalize Induction Chemo, Improve Black Pediatric AML Patients' Outcomes
At ASH, researchers reported that a PGx-based score could identify the cytarabine-based induction therapy young Black patients are most likely to benefit from.